[1] Inman RD, Whittum-Hudson JA, Schumacher HR, et al. Chlamydia and associated arthritis. Curr Opin Rheumatol, 2000,12: 254-262.
[2] Gerard HC, Branigan PJ, Schumacher HR Jr, et al. Synovial Chlamydia trachomatis in patients with reactive arthritis/Reiter's syndrome are viable but show aberrant gene expression. J Rheumatol, 1998, 25: 734-742.
[3] Beatty WL, Morrison RP, Byrne GI. Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbiol Rev, 1994, 58: 686-699.
[4] Koehler L, Nettelnbreker E, Hudson AP, et al. Ultrastructural and molecular analyses of the persistence of Chlamydia trachomatis (serovar K) in human monocytes. Microb Pathog, 1997, 22: 133-142.
[5] Jones ML, Gaston JS, Pearce JH. Induction of abnormal Chlamydia trachomatis by exposure to interferon-gamma or amino acid deprivation and comparative antigenic analysis. Microb Pathog, 2001, 30: 299-309.
[6] Belland R J, Nelson DE, Virok D, et al. Transcriptome analysis of chlamydial growth during IFN-gamma-mediated persistence and reactivation. Proc Natl Acad Sci U S A,2003, 100: 15971-15976.
[7] Byrne GI, Ouellette SP, Wang Z, et al.Chlamydia pneumoniae expresses genes required for DNA replication but not cytokinesis during persistent infection of HEp-2cells. Infect Immun, 2001, 69: 5423-5429.
[8] 邵长庚,靳培英.Reiter综合征.中华皮肤科杂志,2003,36:56-58.
[9] Popov I, Dela Cruz CS, Barber BH, et al.Breakdown of CTL tolerance to self HLAB*2705 induced by exposure to Chlamydia trachomatis. J Immunol, 2002, 169: 4033-4038.
[10] Ramos M, Alvarez I, Sesma L, et al.Molecular mimicry of an HLA-B27-derived ligand of arthritis-linked subtypes with chlamydial proteins. J Biol Chem, 2002,277: 37573-37581.
[11] Hammerschlag MR, Golden NH, Oh MK, et al. Single dose of azithromycin for the treatment of genital chlamydial infections in adolescents. J Pediatr, 1993, 122: 961-965.
[12] Lauhio A, Leirisalo-Repo M, Lahdevirta J,et al. Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis. Arthritis Rheum, 1991, 34: 6-14.
[13] Bardin T, Enel C, Cornelis F, et al. Antibiotic treatment of venereal disease and Reiter's syndrome in a Greenland population.Arthritis Rheum, 1992, 35: 190-194.
[14] SieperJ, FendlerC, LaitkoS, et al. No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: a three-month,multicenter, double -blind, randomized,placebo-controlled study. Arthritis Rheum,1999, 42: 1386-1396.
[15] Laasila K, Laasonen L, Leirisalo-Repo M.Antibiotic treatment and long term prognosis of reactive arthritis. Ann Rheum Dis,2003, 62: 655-658.
[16] Gieffers J, Fullgraf H, Jahn J, et al.Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation, 2001, 103:351-356.
[17] Ford DK, Schulzer M. Synovial lymphocytes indicate "bacterial" agents may cause some cases of rheumatoid arthritis. J Rheumatol,1994, 21: 1447-1449.
[18] Pando, JA, Yarboro, C, El Lallan, A, et al: Prevalence of Chlamydia trachomatis by PCR in the synovium of patients with early rheumatoid arthritis. Arthritis Rheum 1995,38: S287.
[19] Schumacher HR Jr, Gerard HC, Arayssi TK,et al.Lower prevalence of Chlamydia pneumoniae DNA compared with Chlamydia trachomatis DNA in synovial tissue of arthritis patients. Arthritis Rheum, 1999,42: 1889-1893.
[20] Hannu T, Puolakkainen M, Leirisalo-Repo M. Chlamydia pneumoniae as a triggering infection in reactive arthritis. Rheumatology,1999, 38:411-414.
[21] Gerard HC, Schumacher HR, El-Gabalawy H, et al. Chlamydia pneumoniae present in the human synovium are viable and metabolically active. Microb Pathog, 2000,29: 17-24. |
